Source: MedGen UID: 835861⇩ Brincidofovir
An alkoxyalkyl ester prodrug containing the
synthetic, acyclic nucleoside monophosphate
analog cidofovir linked, through its phosphonate
group, to a lipid, 3-hexadecyloxy-1-propanol,
with antiviral activity against double-stranded
DNA viruses. Upon oral administration,
brincidofovir crosses the intestinal wall and
penetrates target viral-infected cells before
being cleaved to the free antiviral agent
cidofovir. In turn, cidofovir is phosphorylated by
pyruvate kinases to its active metabolite
cidofovir diphosphate. Cidofovir diphosphate,
bearing structural similarity to nucleotides,
competes with deoxycytosine-5-triphosphate
(dCTP) for viral DNA polymerase and gets
incorporated into the growing viral DNA
strands. As a result, it prevents further DNA
polymerization and disrupts DNA replication of
viruses. Compared to cidofovir, which is given
shows better oral bioavailability, less toxicity
and enhanced cellular penetration.
31157669 Updates on antiviral drugs for
cytomegalovirus prevention and treatment.
31132546 New vaccines and antiviral drugs for
31116132 Approach to infection and disease
due to adenoviruses in solid organ
31046707 Anti-Ebola therapy for patients with
Ebola virus disease: a systematic review.
30969265 Brincidofovir as a Salvage Therapy in
Controlling Adenoviremia in Pediatric Recipients
of Hematopoietic Stem Cell Transplant.
30677427 In vitro comparison of currently
available and investigational antiviral agents
against pathogenic human double-stranded
DNA viruses: A systematic literature review.
30546071 A survey on incidence and
management of adenovirus infection after
30529090 Antiviral activity of brincidofovir on
30397065 Cidofovir Diphosphate Inhibits
Adenovirus 5 DNA Polymerase via Both
Non-Obligate Chain Termination and Direct
Inhibition, and Polymerase Mutations Confer
Cidofovir Resistance on Intact Virus.
30292744 A randomized, double-blind,
placebo-controlled phase 3 trial of oral
brincidofovir for cytomegalovirus prophylaxis in
allogeneic hematopoietic-cell transplantation.
30154125 Antiviral prophylaxis for
cytomegalovirus infection in allogeneic
hematopoietic cell transplantation.
30153445 In vitro evaluation of current and
novel antivirals in combination against human
30120866 Efficacy of Brincidofovir as
prophylaxis against HSV and VZV in
hematopoietic cell transplant recipients.
30004790 Letermovir for the prevention of
cytomegalovirus infection in adult
stem cell transplant recipients.
29846280 Brincidofovir (CMX001) Toxicity
Associated With Epithelial Apoptosis and Crypt
Drop Out in a Hematopoietic Cell Transplant
Patient: Challenges in Distinguishing Drug
Toxicity From GVHD.
29846196 Adenovirus infection in pediatric
transplant recipients: are effective antiviral
agents coming our way?
29842914 Genetic diversity of the human
adenovirus species C DNA polymerase.
29777868 Comparative Efficacy and Safety of
Different Antiviral Agents for Cytomegalovirus
Prophylaxis in Allogeneic Hematopoietic-Cell
Transplantation: a Systematic Review and
29773767 The Role of Brincidofovir in
Preparation for a Potential Smallpox Outbreak.
29742642 Successful Brincidofovir Treatment
of Metagenomics-Detected Adenovirus
Infection in a Severely Ill STAT1-Deficient
3532035 Open Label Study of IV Brincidofovir
in Adult Transplant Recipients With Adenovirus
3481244 Treatment of Adenovirus
Disseminated Infections in Hematopoietic Stem
Cell Transplant Patients With Adenovirus
2596997 Expanded Access Protocol to Provide
Brincidofovir for the Treatment of Serious
Adenovirus Infection or Disease
2439970 SUSTAIN: A Randomized,
Double-Blind, Multicenter, Phase 3 Study of the
Efficacy, Safety, and Tolerability of Brincidofovir
Versus Valganciclovir for the Prevention of
Cytomegalovirus Disease in CMV Seronegative
Kidney Allograft Recipients
2439957 SURPASS: A Randomized,
Double-Blind, Multicenter Study of the Efficacy,
Safety, and Tolerability of Brincidofovir Versus
Valganciclovir for the Prevention of
Cytomegalovirus (CMV) Disease in CMV
Seropositive Kidney Transplant Recipients (BCV
2271347 An Open-Label, Multicenter Study of
the Safety and Anti Viral Activity of Brincidofovir
(BCV, CMX001) for Ebola Virus Disease
2087306 Phase III, Open-labeled, Multicenter
Study of the Safety and Efficacy of Brincidofovir
(CMX001) in the Treatment of Early Versus Late